Zhejiang Xinguang Pharmaceutical Co Ltd (300519) — Working Capital to Net Assets Ratio
Zhejiang Xinguang Pharmaceutical Co Ltd (300519) has a Working Capital to Net Assets ratio of 85.8% as of September 2025. Working capital of CN¥710.41 Million (current assets of CN¥767.65 Million minus current liabilities of CN¥57.24 Million) is measured against net assets of CN¥827.95 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Zhejiang Xinguang Pharmaceutical Co Ltd (300519) net asset quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Zhejiang Xinguang Pharmaceutical Co Ltd Working Capital to Net Assets (2011–2024)
This chart shows how Zhejiang Xinguang Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the ratio stands at 85.8%, reflecting working capital of CN¥710.41 Million against net assets of CN¥827.95 Million CNY. Check 300519 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Zhejiang Xinguang Pharmaceutical Co Ltd (2011–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Zhejiang Xinguang Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 300519 market cap overview.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 84.8% | CN¥704.11 Million | CN¥830.53 Million | CN¥774.71 Million | CN¥70.61 Million | ▲ +0.9 pp |
| 2023 | 83.9% | CN¥708.09 Million | CN¥844.12 Million | CN¥785.17 Million | CN¥77.08 Million | ▼ -0.4 pp |
| 2022 | 84.3% | CN¥723.90 Million | CN¥858.89 Million | CN¥812.26 Million | CN¥88.37 Million | ▲ +0.3 pp |
| 2021 | 84.0% | CN¥710.69 Million | CN¥846.22 Million | CN¥785.92 Million | CN¥75.22 Million | ▲ +0.5 pp |
| 2020 | 83.5% | CN¥690.58 Million | CN¥826.94 Million | CN¥742.90 Million | CN¥52.31 Million | ▲ +2.4 pp |
| 2019 | 81.1% | CN¥648.47 Million | CN¥799.71 Million | CN¥698.41 Million | CN¥49.93 Million | ▲ +0.9 pp |
| 2018 | 80.2% | CN¥604.11 Million | CN¥753.26 Million | CN¥662.18 Million | CN¥58.07 Million | ▲ +0.1 pp |
| 2017 | 80.1% | CN¥565.23 Million | CN¥705.81 Million | CN¥623.14 Million | CN¥57.91 Million | ▼ -1.4 pp |
| 2016 | 81.5% | CN¥521.90 Million | CN¥640.46 Million | CN¥570.86 Million | CN¥48.95 Million | ▲ +15.6 pp |
| 2015 | 65.9% | CN¥203.81 Million | CN¥309.35 Million | CN¥245.50 Million | CN¥41.69 Million | ▲ +3.7 pp |
| 2014 | 62.2% | CN¥154.83 Million | CN¥249.00 Million | CN¥197.36 Million | CN¥42.53 Million | ▲ +1.4 pp |
| 2013 | 60.8% | CN¥122.72 Million | CN¥201.97 Million | CN¥163.08 Million | CN¥40.36 Million | ▲ +16.6 pp |
| 2012 | 44.1% | CN¥62.48 Million | CN¥141.62 Million | CN¥135.11 Million | CN¥72.64 Million | ▲ +37.4 pp |
| 2011 | 6.7% | CN¥7.03 Million | CN¥104.32 Million | CN¥119.40 Million | CN¥112.36 Million | — |